Allogene Therapeutics Inc (ALLO)

NASDAQ HEALTHCARE
$2.19 -2.67% RSI 42 Neutral Add Alert

Moving Averages

SMA 200
$1.53
Price above

Company Profile

Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.

Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Market Cap
$663.08M
P/E Ratio
None
EPS
$-0.87
Beta
0.536
Dividend Yield
0.00%
52-Week High
$2.95
52-Week Low
$0.862

Similar stocks in BIOTECHNOLOGY

BNTX
BioNTech SE
RSI 57.0
VRTX
Vertex Pharmaceuticals Inc
RSI 41.0
CRSP
CRISPR Therapeutics AG
RSI 50.0
MRNA
Moderna Inc
RSI 36.0
VKTX
Viking Therapeutics Inc
RSI 38.0
SRPT
Sarepta Therapeutics Inc
RSI 51.0

Data last updated: April 11, 2026 at 7:36 PM EDT

Track ALLO for free

Get e-mail RSI alerts when Allogene Therapeutics Inc enters oversold or overbought territory. Free forever.

Add Alert